Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Three to buy
GlaxoSmithKline
(Shares) GSK’s shares are on a deep discount compared to peer AstraZeneca. They yield 6.5% but analysts think dividend cover next year will be tight. Yet the market is missing key strengths: a robust vaccine division – notably thanks to its Shingrix vaccine – and a “strong pipeline” at the oncology franchise. The consumer healthcare joint venture with Pfizer will also unlock cost savings and better margins. On a price/earnings ratio (p/e) of 11 the stock is appealing. Buy. 1,221p
Hiscox
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(The Mail on Sunday) “Should you buy an insurer in the middle of a global catastrophe?” Hiscox is a diversified player, offering everything from “big ticket insurance” of oil rigs to niche retail policies for art and kidnap cover. With Covid-19 striking so broadly this has been a “torrid” year, but recent trading updates suggest the ship is steadying and premium income has kept growing. With the stock down by half since July 2019 Hiscox could prove “a good policy”. 942p
Kingfisher
(Investors Chronicle) Lockdown is no problem for the B&Q and Screwfix-owner, which operates in the UK, France, Poland and Romania. Classified as “essential”, the stores are likely to see a sales surge as housebound Europeans look for something to keep themselves occupied. New management is de-centralising operations to make managers more responsive to local conditions and more people are getting the DIY bug. On 15 times 2022 earnings this is a reasonably-priced turnaround play. Buy. 287p
Three to sell
Dropbox Inc.
(Forbes.com) This cloud-storage specialist reported more than 15 million paying users in the third quarter. Yet its ability to take market share from larger rivals remains in question. The group is struggling to distinguish itself from Google, Apple and Microsoft, which offer more services and are frequently more competitive on price. The shares are priced for implausibly rapid growth. The current valuation implies 46 million paying users by 2027, or 30% of Amazon Prime’s US membership. Given the rich valuation, the risks are tilted to the downside, so avoid. $19
Mercantile Investment Trust
(The Times) This FTSE-250 Trust offers concentrated exposure to the UK market through quality holdings such as Computacenter and Games Workshop. The portfolio is focused on the industrial, financial and consumer sectors but avoids oil and gas. British stocks are trading near 50-year lows and some money managers sense long-term opportunity. Perhaps, but with a double-dip recession looming the FTSE still faces significant headwinds, so all but “the fearless” should avoid. 199p
Ryanair
(The Sunday Telegraph) Ryanair’s latest update showed sales down 78% and a near-€200m after-tax loss over the six months through September. Impressive cost savings and €4.5bn of cash mean that “it will survive” and there will be fewer competitors on the other side of the pandemic. Yet survival is no guarantee of returns, especially with the shares only 14% below their pre-pandemic level. Stick to shares that are less likely to face continued turbulence. €13.34
...and the rest
The Daily Telegraph
Gresham House Strategic Trust has been hoovering up deeply discounted UK micro-cap shares. Patient, risk-tolerant investors could be rewarded when the market turns. Buy (985p). British software “gem” Blancco helps companies delete old data to comply with data-protection laws. It is a leader in this niche and the longer-term growth opportunity is very promising – buy (191p).
Investors Chronicle
US-based Thermo Fisher Scientific is a leading provider of scientific laboratory kit. Business has received a fillip during the coronavirus, while the group should also enjoy a long-term tailwind from rising healthcare spending. Buy ($481).
The Mail on Sunday
Self-storage is a rare bright spot amid the gloom for commercial landlords. Lok’nStore may also gain from the house-buying boom as people need storage space between moves. Hold (565p).
Shares
Newly listed Canadian gold play Wheaton Precious Metals is a “streaming” company – meaning it invests in mining without directly assuming operational risks. There are few comparable businesses on the London market and it offers a new way to buy into the ongoing strength of the yellow metal (3,725p). Microsoft continues to beat analysts’ forecasts thanks to the work-from-home boom, justifying its central role in many a portfolio.Keep buying ($202).
The Times
Packaging firm DS Smith is exposed to the e-commerce boom and on just nine times forecast earnings the shares “look wildly undervalued”.Buy (290p).
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Pensioners ‘running down larger pots’ to avoid inheritance tax as rule change loomsChanges to inheritance tax (IHT) rules for unused pension pots from April 2027 could trigger an ‘exodus of large defined contribution pension pots’, as retirees spend their savings rather than leave their loved ones with an IHT bill.
-
Why do experts think emerging markets will outperform?Emerging markets were one of the top-performing themes of 2025, but they could have further to run as global investors diversify
-
Three Indian stocks poised to profitIndian stocks are making waves. Here, professional investor Gaurav Narain of the India Capital Growth Fund highlights three of his favourites
-
UK small-cap stocks ‘are ready to run’Opinion UK small-cap stocks could be set for a multi-year bull market, with recent strong performance outstripping the large-cap indices
-
Hints of a private credit crisis rattle investorsThere are similarities to 2007 in private credit. Investors shouldn’t panic, but they should be alert to the possibility of a crash.
-
Investing in Taiwan: profit from the rise of Asia’s Silicon ValleyTaiwan has become a technology manufacturing powerhouse. Smart investors should buy in now, says Matthew Partridge
-
‘Why you should mix bitcoin and gold’Opinion Bitcoin and gold are both monetary assets and tend to move in opposite directions. Here's why you should hold both
-
Invest in the beauty industry as it takes on a new lookThe beauty industry is proving resilient in troubled times, helped by its ability to shape new trends, says Maryam Cockar
-
Should you invest in energy provider SSE?Energy provider SSE is going for growth and looks reasonably valued. Should you invest?
-
Has the market misjudged Relx?Relx shares fell on fears that AI was about to eat its lunch, but the firm remains well placed to thrive
